Vijaya Diagnostic Centre Limited has informed the Exchange regarding Audited Financial Results for the quarter and year ended March 31, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Smallcap 250 and 3.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre reported healthy FY25 results with consolidated revenue from operations growing ~24% to Rs 68,139 lakhs (from Rs 54,781 lakhs in FY24) and profit for the year up ~20% to Rs 14,379 lakhs. Standalone revenue rose to Rs 62,714 lakhs with net profit of Rs 13,501 lakhs. Statutory auditor B S R and Co issued an unmodified (clean) opinion on both standalone and consolidated results. The board recommended a final dividend of Rs 2 per share (200% on face value of Re 1), subject to shareholder approval. Additionally, Mr S. Ramachandra Reddy was appointed as Interim CFO and Mr Lanka Sai Srinivas as CTO; 1.91 lakh ESOPs were granted at Rs 815 per option, and the scheme to merge subsidiary Medinova Diagnostic Services awaits final NCLT approval.
Strong topline growth, clean audit, and a 200% dividend signal solid financial health and reward shareholders positively, while the CFO change and pending Medinova merger could draw near-term attention from investors.